CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

CTSA 儿科研究基础设施

• 批准号: 8365151
• 负责人: JOHN Lewis SULLIVAN
• 金额: $ 16.94万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8365151
• 关键词: Clinical Sciences; Massachusetts; Pediatric Research; Research Infrastructure; Translational Research; Universities

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.

该子项目代表CTSA资金百分比的估计值 被用于广泛的研究领域（艾滋病研究，儿科研究或 临床试验）。 列出的总成本只是CTSA数量的估计值 基础设施朝向这一研究领域，而不是直接提供的资金 NCRR授予subproject或subproject人员。 我们已经建立了马萨诸塞大学临床与转化科学中心（UMCCTS），其中包括五个UMass校园。在操作上，该中心位于大学的伍斯特校园，并由医学院管理。该中心是所有UMASS校园的临床和转化科学家的“学术住所”。 CTSA计划将基于世界一流的基础科学的基础建立临床和转化研究，这是诺贝尔生理学或医学奖在2006年授予克雷格·梅洛（Craig Mello）的诺贝尔奖，并于2008年授予维克多·安布罗斯（Victor Ambros）奖。建立创新的研究核心设施；并根据UMass发现开发新的疗法，设备和干预措施； 2）通过招募出色的T2和T3研究领导者以及开发创新的T2/T3核心设施来整合新英格兰中部和马萨诸塞州中部和马萨诸塞州的独特网络，以建立和扩展T2（临床有效性研究）和T3（实施和传播研究）的能力；并增强患者和社区的外展，并参与基于临床/人群的研究； 3）UMCCT将与UMASS系统的所有校园和学校合作，开发计划，课程和教师支持系统，以促进临床和转化研究中的职业。州长迪瓦尔·帕特里克（Deval Patrick）和马萨诸塞州立法机关最近颁布了立法，将国家投资投资10亿美元，直接针对英联邦的生命科学。该大学拥有9000万美元的种子资金，建立了UMass Advanced Therapeutics Cluster（UMATC），其中包括RNA治疗研究所，干细胞生物学和再生医学中心以及基因治疗中心。 UMATC与马萨诸塞州的生物学实验室，梅耶斯初级保健研究所和英联邦医学相连，这是四个在学术中心很少发现的创新组件，以加快临床和翻译研究中社区发现的替补席。相关性（请参阅说明）：马萨诸塞大学临床与转化科学中心（UMCCTS）将通过为所有大学临床研究者提供“学术主页”来改变临床和转化研究的行为。 UMCCT将提供强大的试点赠款计划，综合教育和职业发展计划以及支持和培养临床研究人员的创新核心设施。